Our top pick for
Intersect ENT, Inc is a medical devices business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 402 staff and has a trailing 12-month revenue of around USD$84.1 million.
|52-week range||USD$5.97 - USD$26.98|
|50-day moving average||USD$24.192|
|200-day moving average||USD$20.2021|
|Wall St. target price||USD$23|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.129|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$84.1 million|
|Gross profit TTM||USD$87.4 million|
|Return on assets TTM||-20.89%|
|Return on equity TTM||-62.5%|
|Market capitalisation||USD$802.9 million|
TTM: trailing 12 months
There are currently 965,560 Intersect ENT shares held short by investors – that's known as Intersect ENT's "short interest". This figure is 12.7% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Intersect ENT shares can be evaluated.
Intersect ENT's "short interest ratio" (SIR) is the quantity of Intersect ENT shares currently shorted divided by the average quantity of Intersect ENT shares traded daily (recently around 232105.76923077). Intersect ENT's SIR currently stands at 4.16. In other words for every 100,000 Intersect ENT shares traded daily on the market, roughly 4160 shares are currently held short.
However Intersect ENT's short interest can also be evaluated against the total number of Intersect ENT shares, or, against the total number of tradable Intersect ENT shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intersect ENT's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Intersect ENT shares in existence, roughly 30 shares are currently held short) or 0.0298% of the tradable shares (for every 100,000 tradable Intersect ENT shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Intersect ENT.
Find out more about how you can short Intersect ENT stock.
We're not expecting Intersect ENT to pay a dividend over the next 12 months.
Intersect ENT's shares were split on a 1:4 basis on 11 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.
Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $5.97 up to $26.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.6286. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.